Microglia: Gatekeepers for Neuropathic Pain

Microglia: Gatekeepers for Neuropathic Pain

Overview article

Introduction

Where acute pain protects an individual from further damage, chronic pain serves no adaptive purpose. Approximately 1 in 5 people suffer from chronic pain, which exacts a substantial toll on the both the individual and on national economies (Gaskin and Richard, 2012; Nahin, 2015; Pizzo and Clark, 2012). Chronic pain can arise due to unresolved inflammation (e.g., rheumatoid arthritis), damage to the nervous system (neuropathic pain), and due to unknown precipitating factors (e.g., fibromyalgia). Specific injuries and diseases that can cause neuropathic pain include traumatic injury (e.g. spinal cord injury), stroke, herpes zoster infection (post-herpetic neuralgia), and multiple sclerosis.

A substantial literature has been devoted to understanding neuropathic pain. Basic science studies have revealed that there are key nervous systems sites for pain modulation. These include the site of injury, the cell bodies of primary afferents (dorsal root ganglia; DRG), the dorsal horn of the spinal cord, and a distributed group of brain regions known as the ‘pain matrix’ (Basbaum et al., 2009; Ossipov et al., 2010; Peirs and Seal, 2016; Wiech, 2016). Animal studies have predominantly focused on the spinal cord; this site has particular significance for pain, as primary afferent neurons synapse here with pain projection neurons, and are modulated by descending inhibitory neurons and interneurons (Ossipov et al., 2010; Peirs and Seal, 2016). Therefore, this site will be the focus of this review. Studies in spinal cord have revealed that neuropathic pain is not purely the product of dysfunctional neuronal communication, but that non-neuronal cells, such as microglia, are also critical participants (Grace et al., 2014; Ji et al., 2016).

What is the evidence for involvement of microglia in chronic pain?

Microglia are the resident macrophages of the central nervous system (CNS) and play a key role in maintaining homeostasis. Activation of spinal microglia in response to injury of peripheral nerves was first demonstrated in the late 1990s; immunohistochemical and gene expression studies revealed that microglial ‘activation’ markers were rapidly elevated (Colburn et al., 1997; Tanga et al., 2004). A causal role for microglia in the pain behaviors caused by peripheral nerve injury was then inferred when minocycline treatment was found to prevent pain in rats (Ledeboer et al., 2005a; Raghavendra et al., 2003). A key finding of these and subsequent studies (e.g. (Jin et al., 2003)) was that expression of microglia activation markers peaked within 2 weeks of injury, while inhibition of microglial signaling could prevent, but not reverse, neuropathic pain. This led to the conclusion that microglia participate in the development of neuropathic pain, but not its maintenance. A recent study using Mac1-saporin depletion has claimed that microglia do contribute to the maintenance of neuropathic pain, as their depletion reverses pain behaviors 3 months after nerve injury (Echeverry et al., 2017). However, the consensus view is that microglia are principally early responders to nerve injury.

A limitation to this early research is that pharmacological agents like minocycline also inhibit neurons and astrocytes; the lack of selectivity for microglia confounds interpretation. However, several studies have reinforced evidence for microglial participation in pain. Demonstrating sufficiency for pain, microglia were activated in vitro and then adoptively transferred to naïve male rats, inducing pain behaviors (Tsuda et al., 2003). We have recently expressed Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) in spinal microglia, using a cell-selectively promoter (Grace et al., 2016, 2018). Activation of excitatory DREADDs in naïve male rats induced allodynia (sensitivity to innocuous stimuli), supportive of the sufficiency for microglia activation for pain. We also showed that inhibiting microglia with DREADDs could reverse neuropathic pain in males, which demonstrated that microglia are necessary for neuropathic pain.

There is emerging evidence that microglia may contribute to neuropathic pain in a sex-dependent manner. Acute depletion of microglia or inhibition with minocycline reversed neuropathic pain in male rats only (Sorge et al., 2015). However, these findings are not without controversy (Costigan et al., 2009; Krukowski et al., 2016), and additional studies with longer-term treatments are required; when neuropathic pain is fully developed, repeated treatments are often required for reversal. Nonetheless, the accumulating evidence for males-specific engagement of particular signaling pathways will be discussed.

How do microglia become activated after neuronal injury?

Given the evidence that microglia are important cellular mediators of neuropathic pain, investigators next turned to the question of how microglia can respond to nerve injury.

Microglial activation is understood as a change in cell number, morphology, phenotype and motility, the expression of membrane-bound and intracellular signaling proteins, and the release of immunoregulatory products, such as cytokines and chemokines. Microglia express a range of receptors that detect ligands released as a consequence of neuronal injury, and that lead to their activation.

ATP. Injured neurons release ATP in the dorsal horn of the spinal cord (Masuda et al., 2016), which is detected by purinergic receptors expressed by microglia; these include ionotropic P2X4 and P2X7 receptors, and metabotropic P2Y12 and P2Y13 receptors (Trang et al., 2012; Tsuda, 2017). Microglia upregulate surface expression of these receptors after peripheral nerve injury. Their involvement in neuropathic pain has been confirmed in genetic knockout and knockdown studies, as pain behaviors are reduced under these conditions (Sorge et al., 2012; Tsuda et al., 2003). However, the P2X4R pathway is specifically engaged in male rather than female rodents (Mapplebeck et al., 2018; Sorge et al., 2015). This may be due to differential transcriptional regulation of P2rx4 by the transcription factor IRF5 (Mapplebeck et al., 2018).

Chemokines. Several chemokines are produced and released by injured neurons. At present the strongest evidence supports a role for CSF-1. The cognate receptor CSF-1R is expressed exclusively by microglia in the CNS, and is essential for survival (Elmore et al., 2014). Peripheral nerve injury induces de novo expression of CSF-1 in the DRG (Guan et al., 2016). Conditional knockout of CSF-1 in sensory neurons prevented development of pain behaviors, and reduced microglial activation and proliferation in the spinal dorsal horn (Guan et al., 2016). There is evidence that engagement of this pathway may precede activation of microglia via ATP, as the CSF-1R adapter protein DAP12, is upstream of the P2X4R gene.

Other groups have previously suggested that the chemokines CCL2 and CX3CL1 are neuron-glia signals in neuropathic pain (Abbadie et al., 2003; Milligan et al., 2004). However, subsequent studies revealed that microglia express very low levels of CCR2 (Mizutani et al., 2012), suggesting a limited role for its ligand CCL2. While microglia uniquely express the receptor for CX3CL1 in the CNS (Mizutani et al., 2012), the release of this ligand from neurons is now known to be secondary to microglial activation; CX3CL1 is cleaved by cathepsin S derived from already activated microglia (Clark et al., 2009). Furthermore, DAP12 is also upstream of CX3CR1 and cathepsin S genes (Guan et al., 2016). Thus, CSF-1 appears to be the principal chemokine to mediate microglial activation after peripheral nerve injury.

Damage associated molecular patterns (DAMPs). According to the danger model of immunogenicity (Matzinger, 1994), the immune system can respond to cellular damage and the consequent release of DAMPs. Several DAMPs have been implicated in neuropathic pain, including High Mobility Group Box 1 (HMGB1), Heat shock proteins (HSP)-60 and -90, biglycan and fibrinogen (Lacagnina et al., 2018). These molecules are typically sequestered within intracellular compartments or the extracellular matrix, and become liberated into the extracellular milieu during stress or damage. It should be noted that the cellular source of many of these DAMPs has not been unequivocally demonstrated. Nonetheless, microglia respond to exogenous administration of DAMPs. Pattern recognition receptors are those capable of detecting such DAMPs, and among this receptor class, Toll-like receptors (TLRs) have been most thoroughly investigated (Lacagnina et al., 2018).

Of the 13 TLRs expressed in rodents, most research has focused on TLR4. TLR4 is upregulated after peripheral nerve injury. However, evidence for causal involvement in neuropathic pain comes from pharmacological and genetic manipulations: pain behaviors after nerve injury are attenuated when TLR4 or accessory proteins (required for signaling) are inhibited, knocked out, or knocked down (Hutchinson et al., 2008; Lacagnina et al., 2018; Tanga et al., 2005). There is an emerging role for other TLRs in neuropathic pain, including TLR2, 3, 5, and 9 (Lacagnina et al., 2018).

Finally, TLR4-dependent pain may be sexually dimorphic. Intrathecal injection of the TLR4 agonist LPS induces allodynia in male (but not female) rats (Sorge et al., 2011). This is in notable contrast to intrathecal disulfide HMGB1, which induces allodynia in both male and female mice (Agalave et al., 2014). Reversal of intrathecal LPS-evoked tactile allodynia by the small molecule TLR4 antagonist TAK-242 occurs in male mice, while having no effect on females (Woller et al., 2016) Similarly, male mice deficient in TLR4 do not develop robust neuropathic pain after peripheral nerve injury, whereas female mice do (Stokes et al., 2013). This leads to the intriguing possibility of sex differences regarding the involvement of innate immune signaling in the development of neuropathic tactile hypersensitivity. Given the predominance of chronic pain conditions disproportionately afflicting women, it has been argued that interactions between endocrine and immune mechanisms may help explain some of the sex differences observed in the epidemiology of pain disorders (Mogil and Bailey, 2010; Nicotra et al., 2014).

Intracellular signaling pathways. Many of the receptors described above converge on common intracellular signaling pathways, including activation of the transcription factor NFkB, and p38 and ERK mitogen activated protein kinases (MAPKs). Such activation occurs in spinal microglia after peripheral nerve injury, and leads increased transcription of proinflammatory and pronociceptive cytokines and growth factors (Jin et al., 2003; Ledeboer et al., 2005b; Zhuang et al., 2005). Other signaling pathways include activation of NADPH oxidase isoform 2 that generate reactive oxygen species (Kim et al., 2010). These enzymes and transcription factors are causal to neuropathic pain, as their inhibition or genetic deletion reverses pain behaviors evoked by peripheral nerve injury in male rodents. However, one group has assessed female rodents, and shown that pain behaviors are not reversed when p38 is inhibited (Sorge et al., 2015; Taves et al., 2016). This again points to a male-specific role for microglia in neuropathic pain.

How do activated microglia cause pain?

As noted above, a primary consequence of microglial activation is the release of proinflammatory cytokines, growth factors, and reactive oxygen species. These mediators act at central synapses in the spinal cord dorsal horn to disrupt the balance of excitatory and inhibitory neurotransmission.

Enhanced excitatory synaptic transmission. Cytokines such as TNF and IL-1b increase the excitatory tone of pain projection neurons by enhancing glutamate release and availability (Grace et al., 2014). For example, activation of IL-1 receptors that are functionally coupled to presynaptic NMDA receptors promotes glutamate exocytosis (Yan and Weng, 2013). Both IL-1b and TNF can downregulate transporters expressed by astrocytes that are responsible for uptake of glutamate (Xin et al., 2009; Yan et al., 2014); the consequence is excessive glutamate levels in the synaptic cleft. Cytokines and chemokines can also sensitize post-synaptic terminals. The mechanisms include increased trafficking and surface expression of AMPA receptors, and by phosphorylating NMDA receptor subunits (Gao et al., 2007; Stellwagen and Malenka, 2006; Stellwagen et al., 2005; Zhang et al., 2008). Collectively, these studies show that inflammatory mediators released by microglia have the capacity to facilitate hyperexcitability of pain projection neurons.

Reduced inhibitory synaptic transmission. Mediators derived from microglia can also cause disinhibition. Cytokines, chemokines and reactive oxygen species can diminish release of GABA and glycine from interneurons and descending inhibitory projections in the spinal cord (Gosselin et al., 2005; Kawasaki et al., 2008; Yowtak et al., 2011). Activated microglia also sculpt synaptic elements in the spinal dorsal horn and excessively prune GABAergic terminals (Batti et al., 2016). The growth factor BDNF activates TrkB receptors on postsynaptic terminals, reducing expression of the KCC2 potassium-chloride cotransporter (Coull et al., 2005). This leads to increased intracellular Cl concentrations that weaken GABA receptor mediated hyperpolarization. Only males exhibit BDNF-dependent neuropathic pain (Sorge et al., 2015); this result is consistent with BDNF release requiring P2X4 receptor and p38 MAPK activation, which themselves are activated in a sexually dimorphic manner (Mapplebeck et al., 2018; Taves et al., 2016). The consequence of these disinhibitory mechanisms is to increase the excitability of pain projection neurons.

Future directions and conclusions

A major challenge for the future is to translate the findings from animal models into humans. Imaging studies are yielding very promising results using radioligand binding to TSPO, a putative marker of glial activation. Binding was increased in thalamic nuclei, somatosensory cortices of patients with low back pain (Loggia et al., 2015), and the neuroforamina and spinal cords of patients with lumbar radiculopathy (Albrecht et al., 2018). Further work is required to understand the function of TSPO in neuropathic pain and to develop new radioligands. Firstly, it is unclear whether TSPO expression correlates with activation (Owen et al., 2017). Secondly, there is some evidence that TSPO has anti-inflammatory function (Lee et al., 2016), and thus only a subset of glia may be labelled. Which subset that may be, and its relationship to neuropathic pain, need to be defined. Finally, the selectivity of TSPO to microglia is a matter of debate that needs clarification (Crawshaw and Robertson, 2017). Nonetheless, these studies provide compelling evidence for the association of glial activation in human chronic pain states. PET imaging may also be a useful tool to validate target engagement for development of novel therapeutics that target microglia.

The vast majority of studies have focused on microglia in the spinal cord. However, the sensory and affective components of chronic pain are ultimately encoded in the brain, as noted above. Several groups, including my own, are now beginning the investigate how microglia in the brain contribute to the multi-dimensional experience of chronic pain (Grace and Lacagnina, 2018; Taylor et al., 2015).

The evidence summarized here highlights a critical role for microglia in the initiation of neuropathic pain, especially in male rodents. Given that women predominantly suffer with chronic pain, studies should now be directed towards identifying whether microglia are truly a relevant clinical target for treatment of chronic pain; dysfunctional synaptic plasticity induced by activated microglia is a promising therapeutic avenue for a disease that is poorly managed and causes untold suffering.

Author Affiliations:

Peter M. Grace, PhD – Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030; e: pgrace@mdanderson.org

List of Non-Standard Abbreviations


CNS, central nervous system; DRG, dorsal root ganglia; DREADDs, designer receptor exclusively activated by a designer drug; DAMP, damage associated molecular pattern; IL-1, interleukin-1; TLR, toll-like receptor; TNF, tumor necrosis factor.


References

Abbadie, C., Lindia, J.A., Cumiskey, A.M., Peterson, L.B., Mudgett, J.S., Bayne, E.K., DeMartino, J.A., MacIntyre, D.E., and Forrest, M.J. (2003). Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc. Natl. Acad. Sci. U. S. A. 100, 7947–7952.

Agalave, N.M., Larsson, M., Abdelmoaty, S., Su, J., Baharpoor, A., Lundbäck, P., Palmblad, K., Andersson, U., Harris, H., and Svensson, C.I. (2014). Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis. Pain 155, 1802–1813.

Albrecht, D.S., Ahmed, S.U., Kettner, N.W., Borra, R.J.H., Cohen-Adad, J., Deng, H., Houle, T.T., Opalacz, A., Roth, S.A., Melo, M.F.V., et al. (2018). Neuroinflammation of the spinal cord and nerve roots in chronic radicular pain patients. Pain 159, 968–977.

Basbaum, A.I., Bautista, D.M., Scherrer, G., and Julius, D. (2009). Cellular and Molecular Mechanisms of Pain. Cell 139, 267–284.

Batti, L., Sundukova, M., Murana, E., Pimpinella, S., De Castro Reis, F., Pagani, F., Wang, H., Pellegrino, E., Perlas, E., Di Angelantonio, S., et al. (2016). TMEM16F Regulates Spinal Microglial Function in Neuropathic Pain States. Cell Rep. 15, 2608–2615.

Clark, A.K., Yip, P.K., and Malcangio, M. (2009). The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J. Neurosci. 29, 6945–6954.

Colburn, R.W., DeLeo, J.A., Rickman, A.J., Yeager, M.P., Kwon, P., and Hickey, W.F. (1997). Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J. Neuroimmunol. 79, 163–175.

Costigan, M., Moss, A., Latremoliere, A., Johnston, C., Verma-Gandhu, M., Herbert, T.A., Barrett, L., Brenner, G.J., Vardeh, D., Woolf, C.J., et al. (2009). T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J. Neurosci. 29, 14415–14422.

Coull, J.A.M., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., Gravel, C., Salter, M.W., and De Koninck, Y. (2005). BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438, 1017–1021.

Crawshaw, A.A., and Robertson, N.P. (2017). The role of TSPO PET in assessing neuroinflammation. J. Neurol. 264, 1825–1827.

Echeverry, S., Shi, X.Q., Yang, M., Huang, H., Wu, Y., Lorenzo, L.-E., Perez-Sanchez, J., Bonin, R.P., De Koninck, Y., and Zhang, J. (2017). Spinal microglia are required for long-term maintenance of neuropathic pain. Pain 158, 1792–1801.

Elmore, M.R.P., Najafi, A.R., Koike, M.A., Dagher, N.N., Spangenberg, E.E., Rice, R.A., Kitazawa, M., Matusow, B., Nguyen, H., West, B.L., et al. (2014). Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380–397.

Gao, X., Kim, H.K., Chung, J.M., and Chung, K. (2007). Reactive oxygen species (ROS) are involved in enhancement of NMDA-receptor phosphorylation in animal models of pain. Pain 131, 262–271.

Gaskin, D.J., and Richard, P. (2012). The economic costs of pain in the United States. J. Pain Off. J. Am. Pain Soc. 13, 715–724.

Gosselin, R.D., Varela, C., Banisadr, G., Mechighel, P., Rostene, W., Kitabgi, P., and Melik-Parsadaniantz, S. (2005). Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones. J. Neurochem. 95, 1023–1034.

Grace, P., and Lacagnina, M. (2018). Mapping microglial reactivity in the ‘pain matrix’ after peripheral nerve injury. J. Pain 19, S98.

Grace, P.M., Hutchinson, M.R., Maier, S.F., and Watkins, L.R. (2014). Pathological pain and the neuroimmune interface. Nat. Rev. Immunol. 14, 217–231.

Grace, P.M., Strand, K.A., Galer, E.L., Urban, D.J., Wang, X., Baratta, M.V., Fabisiak, T.J., Anderson, N.D., Cheng, K., Greene, L.I., et al. (2016). Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc. Natl. Acad. Sci. U. S. A. 113, E3441-3450.

Grace, P.M., Wang, X., Strand, K.A., Baratta, M.V., Zhang, Y., Galer, E.L., Yin, H., Maier, S.F., and Watkins, L.R. (2018). DREADDed microglia in pain: Implications for spinal inflammatory signaling in male rats. Exp. Neurol. 304, 125–131.

Guan, Z., Kuhn, J.A., Wang, X., Colquitt, B., Solorzano, C., Vaman, S., Guan, A.K., Evans-Reinsch, Z., Braz, J., Devor, M., et al. (2016). Injured sensory neuron-derived CSF1 induces microglial proliferation and DAP12-dependent pain. Nat. Neurosci. 19, 94–101.

Hutchinson, M.R., Zhang, Y., Brown, K., Coats, B.D., Shridhar, M., Sholar, P.W., Patel, S.J., Crysdale, N.Y., Harrison, J.A., Maier, S.F., et al. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur. J. Neurosci. 28, 20–29.

Ji, R.-R., Chamessian, A., and Zhang, Y.-Q. (2016). Pain regulation by non-neuronal cells and inflammation. Science 354, 572–577.

Jin, S.-X., Zhuang, Z.-Y., Woolf, C.J., and Ji, R.-R. (2003). p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J. Neurosci. 23, 4017–4022.

Kawasaki, Y., Zhang, L., Cheng, J.-K., and Ji, R.-R. (2008). Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J. Neurosci. 28, 5189–5194.

Kim, D., You, B., Jo, E.-K., Han, S.-K., Simon, M.I., and Lee, S.J. (2010). NADPH oxidase 2-derived reactive oxygen species in spinal cord microglia contribute to peripheral nerve injury-induced neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 107, 14851–14856.

Krukowski, K., Eijkelkamp, N., Laumet, G., Hack, C.E., Li, Y., Dougherty, P.M., Heijnen, C.J., and Kavelaars, A. (2016). CD8+ T Cells and Endogenous IL-10 Are Required for Resolution of Chemotherapy-Induced Neuropathic Pain. J. Neurosci. 36, 11074–11083.

Lacagnina, M.J., Watkins, L.R., and Grace, P.M. (2018). Toll-like receptors and their role in persistent pain. Pharmacol. Ther. 184, 145–158.

Ledeboer, A., Sloane, E.M., Milligan, E.D., Frank, M.G., Mahony, J.H., Maier, S.F., and Watkins, L.R. (2005a). Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115, 71–83.

Ledeboer, A., Gamanos, M., Lai, W., Martin, D., Maier, S.F., Watkins, L.R., and Quan, N. (2005b). Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur. J. Neurosci. 22, 1977–1986.

Lee, J.-W., Nam, H., and Yu, S.-W. (2016). Systematic Analysis of Translocator Protein 18 kDa (TSPO) Ligands on Toll-like Receptors-mediated Pro-inflammatory Responses in Microglia and Astrocytes. Exp. Neurobiol. 25, 262–268.

Loggia, M.L., Chonde, D.B., Akeju, O., Arabasz, G., Catana, C., Edwards, R.R., Hill, E., Hsu, S., Izquierdo-Garcia, D., Ji, R.-R., et al. (2015). Evidence for brain glial activation in chronic pain patients. Brain J. Neurol. 138, 604–615.

Mapplebeck, J.C.S., Dalgarno, R., Tu, Y., Moriarty, O., Beggs, S., Kwok, C.H.T., Halievski, K., Assi, S., Mogil, J.S., Trang, T., et al. (2018). Microglial P2X4R-evoked pain hypersensitivity is sexually dimorphic in rats. Pain.

Masuda, T., Ozono, Y., Mikuriya, S., Kohro, Y., Tozaki-Saitoh, H., Iwatsuki, K., Uneyama, H., Ichikawa, R., Salter, M.W., Tsuda, M., et al. (2016). Dorsal horn neurons release extracellular ATP in a VNUT-dependent manner that underlies neuropathic pain. Nat. Commun. 7, 12529.

Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991–1045.

Milligan, E.D., Zapata, V., Chacur, M., Schoeniger, D., Biedenkapp, J., O’Connor, K.A., Verge, G.M., Chapman, G., Green, P., Foster, A.C., et al. (2004). Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur. J. Neurosci. 20, 2294–2302.

Mizutani, M., Pino, P.A., Saederup, N., Charo, I.F., Ransohoff, R.M., and Cardona, A.E. (2012). The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J. Immunol. 188, 29–36.

Mogil, J.S., and Bailey, A.L. (2010). Sex and gender differences in pain and analgesia. Prog. Brain Res. 186, 141–157.

Nahin, R.L. (2015). Estimates of pain prevalence and severity in adults: United States, 2012. J. Pain 16, 769–780.

Nicotra, L., Tuke, J., Grace, P.M., Rolan, P.E., and Hutchinson, M.R. (2014). Sex differences in mechanical allodynia: how can it be preclinically quantified and analyzed? Front. Behav. Neurosci. 8, 40.

Ossipov, M.H., Dussor, G.O., and Porreca, F. (2010). Central modulation of pain. J. Clin. Invest. 120, 3779–3787.

Owen, D.R., Narayan, N., Wells, L., Healy, L., Smyth, E., Rabiner, E.A., Galloway, D., Williams, J.B., Lehr, J., Mandhair, H., et al. (2017). Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. J. Cereb. Blood Flow Metab. 37, 2679–2690.

Peirs, C., and Seal, R.P. (2016). Neural circuits for pain: Recent advances and current views. Science 354, 578–584.

Pizzo, P.A., and Clark, N.M. (2012). Alleviating suffering 101–pain relief in the United States. N. Engl. J. Med. 366, 197–199.

Raghavendra, V., Tanga, F., and DeLeo, J.A. (2003). Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306, 624–630.

Sorge, R.E., LaCroix-Fralish, M.L., Tuttle, A.H., Sotocinal, S.G., Austin, J.-S., Ritchie, J., Chanda, M.L., Graham, A.C., Topham, L., Beggs, S., et al. (2011). Spinal cord Toll-like receptor 4 mediates inflammatory and neuropathic hypersensitivity in male but not female mice. J. Neurosci. 31, 15450–15454.

Sorge, R.E., Trang, T., Dorfman, R., Smith, S.B., Beggs, S., Ritchie, J., Austin, J.-S., Zaykin, D.V., Vander Meulen, H., Costigan, M., et al. (2012). Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat. Med. 18, 595–599.

Sorge, R.E., Mapplebeck, J.C.S., Rosen, S., Beggs, S., Taves, S., Alexander, J.K., Martin, L.J., Austin, J.-S., Sotocinal, S.G., Chen, D., et al. (2015). Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat. Neurosci. 18, 1081–1083.

Stellwagen, D., and Malenka, R.C. (2006). Synaptic scaling mediated by glial TNF-alpha. Nature 440, 1054–1059.

Stellwagen, D., Beattie, E.C., Seo, J.Y., and Malenka, R.C. (2005). Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J. Neurosci. 25, 3219–3228.

Stokes, J.A., Cheung, J., Eddinger, K., Corr, M., and Yaksh, T.L. (2013). Toll-like receptor signaling adapter proteins govern spread of neuropathic pain and recovery following nerve injury in male mice. J. Neuroinflammation 10, 148.

Tanga, F.Y., Raghavendra, V., and DeLeo, J.A. (2004). Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem. Int. 45, 397–407.

Tanga, F.Y., Nutile-McMenemy, N., and DeLeo, J.A. (2005). The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc. Natl. Acad. Sci. U. S. A. 102, 5856–5861.

Taves, S., Berta, T., Liu, D.-L., Gan, S., Chen, G., Kim, Y.H., Van de Ven, T., Laufer, S., and Ji, R.-R. (2016). Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord. Brain. Behav. Immun. 55, 70–81.

Taylor, A.M.W., Castonguay, A., Taylor, A.J., Murphy, N.P., Ghogha, A., Cook, C., Xue, L., Olmstead, M.C., De Koninck, Y., Evans, C.J., et al. (2015). Microglia disrupt mesolimbic reward circuitry in chronic pain. J. Neurosci. 35, 8442–8450.

Trang, T., Beggs, S., and Salter, M.W. (2012). ATP receptors gate microglia signaling in neuropathic pain. Exp. Neurol. 234, 354–361.

Tsuda, M. (2017). P2 receptors, microglial cytokines and chemokines, and neuropathic pain. J. Neurosci. Res. 95, 1319–1329.

Tsuda, M., Shigemoto-Mogami, Y., Koizumi, S., Mizokoshi, A., Kohsaka, S., Salter, M.W., and Inoue, K. (2003). P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424, 778–783.

Wiech, K. (2016). Deconstructing the sensation of pain: The influence of cognitive processes on pain perception. Science 354, 584–587.

Woller, S.A., Ravula, S.B., Tucci, F.C., Beaton, G., Corr, M., Isseroff, R.R., Soulika, A.M., Chigbrow, M., Eddinger, K.A., and Yaksh, T.L. (2016). Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state. Brain. Behav. Immun. 56, 271–280.

Xin, W.-J., Weng, H.-R., and Dougherty, P.M. (2009). Plasticity in expression of the glutamate transporters GLT-1 and GLAST in spinal dorsal horn glial cells following partial sciatic nerve ligation. Mol. Pain 5, 15.

Yan, X., and Weng, H.-R. (2013). Endogenous interleukin-1β in neuropathic rats enhances glutamate release from the primary afferents in the spinal dorsal horn through coupling with presynaptic N-methyl-D-aspartic acid receptors. J. Biol. Chem. 288, 30544–30557.

Yan, X., Yadav, R., Gao, M., and Weng, H.-R. (2014). Interleukin-1 beta enhances endocytosis of glial glutamate transporters in the spinal dorsal horn through activating protein kinase C. Glia 62, 1093–1109.

Yowtak, J., Lee, K.Y., Kim, H.Y., Wang, J., Kim, H.K., Chung, K., and Chung, J.M. (2011). Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. Pain 152, 844–852.

Zhang, R.-X., Li, A., Liu, B., Wang, L., Ren, K., Zhang, H., Berman, B.M., and Lao, L. (2008). IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain 135, 232–239.

Zhuang, Z.-Y., Gerner, P., Woolf, C.J., and Ji, R.-R. (2005). ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 114, 149–159.

Source: Cover Image: Rat cerebellar molecular layer stained with IBA-1 antibody which reveals microglial cells (red). Bergmann glia are revealed in green with antibody to GFAP. Nuclear DNA is shown in blue with DAPI stain. Antibodies and image generated by EnCor Biotechnology Inc.; Author: GerryShaw; Credit: Wikimedia, https://commons.wikimedia.org/wiki/File:Microglial_cells_(red)_in_rat_cerebellar_molecular_layer.jpg

You must be logged in to post a comment Login